[203Pb]VMT01

DRUG2 trials

Sponsors

Perspective Therapeutics

Conditions

Melanoma (Skin)Melanoma Stage IIIMelanoma Stage IVMelanoma, MucosalMelanoma, UvealMetastatic MelanomaRecurrent Melanoma (Skin)

Phase 1

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

CompletedNCT04904120

Perspective TherapeuticsMelanoma, Mucosal, Melanoma (Skin), Melanoma Stage IV +1

Start: 2021-03-05End: 2022-09-20Updated: 2023-11-07

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

RecruitingNCT05655312

Perspective TherapeuticsMelanoma Stage III, Melanoma Stage IV, Metastatic Melanoma +1

Start: 2023-06-01End: 2029-12-31Target: 300Updated: 2026-06-10

Related Papers

A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ <sup>212</sup> Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.

Journal of Clinical Oncology2026-05-28

Interim safety and efficacy data of [ <sup>212</sup> Pb]VMT01 in MC1R expressing melanoma.

Journal of Clinical Oncology2025-05-281 citations

A phase I/IIa of [<sup>212</sup>Pb]VMT01 targeted a-particle therapy for unresectable or metastatic melanoma.

Journal of Clinical Oncology2024-06-017 citations